SS-31 (Elamipretide): A Comprehensive Research Monograph

Overview

SS-31, also known as elamipretide, Bendavia, and MTP-131, is a synthetic mitochondria-targeted tetrapeptide belonging to the Szeto-Schiller (SS) family of cell-permeable peptides. Developed through a collaboration between Dr. Hazel H. Szeto and Dr. Peter W. Schiller, SS-31 was originally identified during a systematic investigation of opioid peptide analogs, when the serendipitous discovery was made that certain aromatic-cationic tetrapeptides selectively concentrated within mitochondria at ratios exceeding 1000-fold relative to the extracellular space. This finding redirected the research program from opioid pharmacology toward mitochondrial medicine, establishing an entirely new class of mitochondria-targeted therapeutics.

The peptide has the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt represents 2’,6’-dimethyltyrosine, a non-natural aromatic amino acid. Its molecular formula is C32H49N7O5 with a molecular weight of approximately 640.8 Da. The structure features alternating cationic (D-Arg, Lys) and aromatic (Dmt, Phe) residues that create an amphipathic motif essential for its biological activity. The D-configuration of the arginine residue confers resistance to aminopeptidase degradation, while the C-terminal amidation enhances metabolic stability and membrane interaction.

SS-31’s primary pharmacological target is cardiolipin, an anionic diphosphatidylglycerol lipid found exclusively on the inner mitochondrial membrane (IMM). Cardiolipin plays an indispensable role in maintaining cristae architecture, organizing the electron transport chain (ETC) into supercomplexes for efficient oxidative phosphorylation, and regulating the interaction between cytochrome c and the mitochondrial membrane. By selectively binding cardiolipin, SS-31 stabilizes cristae structure, optimizes electron transfer through the ETC, and reduces reactive oxygen species (ROS) generation at its source rather than scavenging ROS after their production.

A critical distinction separates SS-31 from earlier mitochondria-targeted compounds such as MitoQ and SkQ1, which rely on triphenylphosphonium (TPP+) cations for mitochondrial accumulation. TPP+-based agents depend on the mitochondrial membrane potential for uptake and can paradoxically depolarize mitochondria at therapeutic concentrations. SS-31’s uptake, by contrast, is independent of membrane potential, enabling it to accumulate effectively in depolarized or dysfunctional mitochondria precisely where therapeutic intervention is most needed. Furthermore, SS-31 exerts no measurable effect on mitochondrial function in healthy cells and organisms, demonstrating a remarkable selectivity for pathological states.

Since its initial characterization, SS-31 has been investigated in over 300 published preclinical studies spanning cardiovascular disease, neurodegenerative disorders, metabolic syndrome, kidney injury, skeletal muscle dysfunction, and aging. It has advanced into multiple clinical trials under the name elamipretide, including programs for heart failure (EMBRACE, PROGRESS-HF), Barth syndrome (TAZPOWER), primary mitochondrial myopathy (MMPOWER-3), and age-related macular degeneration (ReCLAIM).

Mechanism of Action

SS-31’s therapeutic activity centers on its selective interaction with cardiolipin and the downstream consequences of this interaction on mitochondrial membrane properties, electron transport chain function, and cristae architecture. Over the past decade, mechanistic understanding has evolved substantially from early descriptions of ROS scavenging to a more nuanced model involving membrane electrostatic modulation and protein-lipid interaction optimization.

Cardiolipin Binding and Cristae Stabilization

SS-31 binds cardiolipin with high affinity through a combination of electrostatic interactions (between the cationic D-Arg and Lys residues and the anionic phosphate headgroups of cardiolipin) and hydrophobic partitioning (the aromatic Dmt and Phe residues penetrate into the acyl chain region of the lipid bilayer). Nuclear magnetic resonance (NMR) studies by Birk and colleagues demonstrated that the aromatic residues of SS-31 insert deeply into cardiolipin-containing bilayers in an approximately 1:1 stoichiometric ratio with cardiolipin molecules. This interaction stabilizes the hexagonal II phase propensity of cardiolipin that is critical for maintaining the tight curvature of mitochondrial cristae membranes.

During ischemia, loss of cardiolipin integrity causes cristae dissolution, mitochondrial swelling, and catastrophic loss of ATP-generating capacity. Birk and colleagues showed that pretreatment with SS-31 preserved cristae ultrastructure during renal ischemia, prevented mitochondrial swelling, and enabled rapid ATP recovery upon reperfusion. This cristae-protective effect is now recognized as a central component of SS-31’s mechanism across multiple organ systems.

Cytochrome c / Cardiolipin Interaction

Under normal physiological conditions, cytochrome c functions as a mobile electron carrier shuttling electrons between Complex III and Complex IV of the ETC. However, when cytochrome c forms a hydrophobic complex with cardiolipin, it undergoes a conformational change that converts it from an electron carrier into a peroxidase enzyme. This cytochrome c peroxidase activity catalyzes cardiolipin peroxidation, which further destabilizes the inner mitochondrial membrane and initiates a self-amplifying cycle of mitochondrial damage.

SS-31 inhibits the peroxidase activity of the cytochrome c/cardiolipin complex while preserving and even enhancing cytochrome c’s electron carrier function. This dual action simultaneously reduces oxidative damage to cardiolipin and maintains efficient electron flux through the ETC. Importantly, this mechanism explains why SS-31 reduces ROS without being a direct ROS scavenger: by preventing the formation of the cytochrome c/cardiolipin peroxidase complex, SS-31 eliminates a primary source of mitochondrial ROS generation rather than neutralizing ROS after they are produced.

Membrane Electrostatic Modulation

More recent biophysical investigations by Mitchell and colleagues have revealed an additional layer of SS-31’s mechanism. Using model membranes and isolated mitochondria, they demonstrated that SS-31 partitions into the membrane interfacial region with an affinity that correlates directly with surface charge density. The polybasic peptide modulates the surface electrostatics of both model and mitochondrial membranes in a saturable manner. This electrostatic modulation alters the distribution of divalent cations, including calcium, at the membrane interface and reduces the energetic burden of calcium stress on mitochondria.

Protein Interaction Landscape

Chemical cross-linking coupled with mass spectrometry (XL-MS) has identified the specific mitochondrial protein partners of SS-31. Chavez and colleagues found that SS-31 interacts with two functionally distinct groups of cardiolipin-binding proteins: those involved in oxidative phosphorylation (including subunits of Complexes I, III, IV, and V, as well as the ADP/ATP carrier) and those involved in 2-oxoglutarate metabolic processes. The cross-linked residues map to regions proximal to known cardiolipin-protein binding interfaces, consistent with a mechanism in which SS-31 modulates these interactions by altering the local lipid environment.

Pharmacokinetics

The pharmacokinetics of SS-31 have been characterized in multiple animal species and in early-phase human clinical trials, providing a relatively detailed profile for a mitochondria-targeted peptide therapeutic.

Absorption and Distribution

SS-31 is cell-permeable and freely crosses plasma membranes without requiring active transport mechanisms or receptor-mediated uptake. Following subcutaneous injection in clinical trials, the peptide is rapidly absorbed with peak plasma concentrations occurring within 1 to 2 hours. The compound distributes rapidly to mitochondria-rich tissues, concentrating within mitochondria at ratios exceeding 1000-fold relative to the extracellular compartment. Unlike TPP+-conjugated compounds, this mitochondrial accumulation is independent of the mitochondrial membrane potential, enabling SS-31 to target depolarized mitochondria in disease states.

In the EMBRACE heart failure trial, intravenous infusion of elamipretide at doses of 0.005, 0.05, and 0.25 mg/kg/h produced dose-proportional peak plasma concentrations that occurred at end-of-infusion and were undetectable by 24 hours post-infusion, indicating rapid clearance from plasma.

Metabolism and Elimination

As a small tetrapeptide, SS-31 is subject to proteolytic degradation; however, the D-configuration arginine at position 1 and the C-terminal amidation provide substantial resistance to aminopeptidases and carboxypeptidases, respectively. The dimethyltyrosine residue further contributes to metabolic stability. Detailed metabolite identification has not been published, but the compound’s rapid clearance from plasma suggests efficient distribution into tissues and eventual degradation to constituent amino acids.

Route Considerations

In preclinical studies, SS-31 has been administered via intraperitoneal (most common in rodent studies), subcutaneous (preferred in larger animal and clinical studies), and intravenous routes. Clinical development has focused on subcutaneous injection for chronic administration. Unlike BPC-157, SS-31 has not demonstrated oral bioavailability due to its small size and susceptibility to gastrointestinal proteases, though its D-amino acid content provides partial resistance.

Research Applications

Cardiovascular Protection and Heart Failure

Heart failure research represents the most clinically advanced application of SS-31/elamipretide. The failing heart is characterized by profound mitochondrial dysfunction, including diminished oxidative phosphorylation, cardiolipin depletion, disrupted cristae architecture, and abnormal mitochondrial dynamics favoring excessive fission.

In a landmark preclinical study, Sabbah and colleagues treated dogs with advanced microembolization-induced heart failure with subcutaneous elamipretide (0.5 mg/kg daily) for three months. Treated animals showed significant improvement in left ventricular ejection fraction (from 30% to 36%), substantial reduction in NT-proBNP levels (774 pg/mL decrease), normalization of plasma TNF-alpha and C-reactive protein, and restoration of mitochondrial state-3 respiration, membrane potential, and ATP/ADP ratio (from 0.38 in controls to 1.16 in treated animals). Notably, these improvements were observed with monotherapy, without concurrent standard heart failure medications.

Further mechanistic work by the same group demonstrated that long-term elamipretide therapy normalized a broad range of mitochondrial dynamics abnormalities in the failing heart, including restoration of eNOS-cGMP-PGC-1alpha signaling (the master regulator of mitochondrial biogenesis), correction of the fission/fusion balance (reducing Fis1 and DRP-1 while increasing MFN-2 and OPA-1), restoration of mitofilin (a key cristae junction protein), and normalization of cardiolipin synthesis and remodeling enzymes (CL synthase-1, tafazzin-1, ALCAT-1).

Critically, Chatfield and colleagues demonstrated that elamipretide’s effects translate to human cardiac tissue. In freshly explanted failing and nonfailing ventricular tissue from children and adults, ex vivo treatment with elamipretide significantly improved mitochondrial oxygen flux, Complex I and Complex IV activities, and supercomplex-associated Complex IV activity. These results confirmed that the mitochondrial defects in human heart failure are amenable to pharmacological correction by cardiolipin-targeted therapy.

In clinical trials, the EMBRACE study (first-in-human for HFrEF) demonstrated that a single 4-hour intravenous infusion of elamipretide was safe and well tolerated, with the highest dose cohort (0.25 mg/kg/h) showing significant reductions in left ventricular end-diastolic volume (-18 mL, P=0.009) and end-systolic volume (-14 mL, P=0.005) compared to placebo. The subsequent PROGRESS-HF Phase 2 trial evaluated 28 days of daily subcutaneous elamipretide (4 mg or 40 mg) in 71 patients with HFrEF. While the drug was well tolerated, it did not demonstrate significant improvement in LVESV compared to placebo over this treatment period, suggesting that longer treatment durations may be necessary to observe structural cardiac remodeling.

Barth Syndrome

Barth syndrome (BTHS) represents a particularly compelling indication for SS-31 because the genetic defect in tafazzin directly impairs cardiolipin remodeling, making it the prototypical cardiolipin-related disease. BTHS patients exhibit up to 95% reduction in mature (tetralinoleoyl) cardiolipin, with a corresponding accumulation of monolysocardiolipin (MLCL), leading to mitochondrial dysfunction, cardiomyopathy, skeletal myopathy, and neutropenia.

Russo and colleagues investigated SS-31 in tafazzin-knockdown (Taz-KD) mice, the standard preclinical model for BTHS. Cardiac mitochondria from Taz-KD mice displayed the characteristic MALDI-TOF/MS cardiolipin fingerprint of BTHS, along with reduced respiratory capacity. In vivo SS-31 treatment improved mitochondrial respiratory rates and promoted supercomplex organization without altering the MLCL/CL ratio. This finding was mechanistically significant because it demonstrated that SS-31 could restore mitochondrial function by optimizing the biophysical properties of the remaining cardiolipin rather than requiring correction of the underlying lipid abnormality.

Follow-up work by the same group revealed that SS-31 also corrected ultrastructural abnormalities in Taz-KD cardiac mitochondria, including restoration of normal cristae morphology, correction of pro-fission conditions, and improvement of defective mitophagy pathways. These findings suggest that SS-31’s cardiolipin interaction has broad downstream effects on mitochondrial quality control mechanisms beyond respiratory chain function alone.

Aging and Neurovascular Function

Age-related mitochondrial dysfunction is increasingly recognized as a central mechanism underlying the decline in function across multiple organ systems during aging. SS-31 has emerged as one of the most extensively studied interventions for age-related mitochondrial decline.

Tarantini and colleagues demonstrated that treatment of 24-month-old mice with SS-31 (10 mg/kg/day, intraperitoneal) for just two weeks significantly improved neurovascular coupling responses by enhancing nitric oxide-mediated cerebromicrovascular dilation. These vascular improvements were associated with significant gains in spatial working memory, motor skill learning, and gait coordination. At the cellular level, SS-31 reduced mitochondrial ROS production and improved mitochondrial respiration in cerebromicrovascular endothelial cells derived from aged animals.

These findings are consistent with the broader concept that mitochondrial oxidative stress drives age-related vascular dysfunction and cognitive decline, and that targeted mitochondrial intervention can reverse established age-related deficits rather than merely slowing their progression.

Skeletal Muscle Function

Skeletal muscle is among the most mitochondria-dense tissues in the body, and its function is particularly sensitive to mitochondrial impairment. In heart failure, skeletal muscle mitochondrial dysfunction contributes to exercise intolerance, a cardinal symptom that significantly impacts quality of life.

Sabbah and colleagues examined the effects of elamipretide on skeletal muscle in dogs with heart failure. Heart failure was associated with a shift from type 1 (oxidative) to type 2 (glycolytic) muscle fibers, along with impaired mitochondrial respiration, membrane potential, ATP synthesis, and cytochrome c oxidase activity. Three months of elamipretide treatment restored near-normal fiber-type composition (type 1 fibers: 23% in HF controls versus 31% in treated animals versus 32% in normal dogs). In vitro exposure of skeletal muscle mitochondria to elamipretide produced dose-dependent normalization of all mitochondrial function parameters. Notably, elamipretide had no effect on mitochondria from normal skeletal muscle, further underscoring its selectivity for dysfunctional mitochondria.

Neuroprotection and Cognitive Function

Beyond age-related neurovascular effects, SS-31 has demonstrated neuroprotective properties in models of neuroinflammation, neurodegenerative disease, and neurological injury. Zhao and colleagues showed that SS-31 attenuated LPS-induced mitochondrial dysfunction, oxidative stress, neuroinflammation, and synaptic damage in mice. Elamipretide treatment preserved dendritic spine density in the hippocampus, upregulated brain-derived neurotrophic factor (BDNF) signaling, and reversed deficits in hippocampus-dependent learning and memory. The authors proposed SS-31 as a potential therapeutic strategy for perioperative neurocognitive disorders, where neuroinflammation-driven mitochondrial damage underlies cognitive impairment.

Safety Profile

SS-31/elamipretide has demonstrated a favorable safety profile across both extensive preclinical testing and multiple clinical trials.

Preclinical Safety

In animal studies spanning multiple species (mice, rats, dogs), SS-31 has been administered at doses ranging from 0.01 to 10 mg/kg/day for durations up to three months without significant adverse effects. No organ toxicity, behavioral changes, or mortality attributable to SS-31 treatment has been reported. The compound’s selectivity for dysfunctional mitochondria, with no measurable effect on healthy mitochondria, provides an inherent margin of safety.

Clinical Safety Data

In the EMBRACE trial, single intravenous infusions of elamipretide at doses up to 0.25 mg/kg/h for four hours produced no serious adverse events, with stable blood pressure and heart rate across all dose cohorts. In the PROGRESS-HF trial, 28 days of daily subcutaneous elamipretide at doses up to 40 mg was well tolerated with rates of study drug-related adverse events similar across treatment and placebo groups. Injection site reactions have been the most commonly reported adverse events with subcutaneous administration.

Potential Interactions

SS-31’s mechanism of action through cardiolipin modulation suggests potential interactions with other agents that affect mitochondrial function, including cyclosporine A (which inhibits the mitochondrial permeability transition pore), doxorubicin (which generates mitochondrial ROS), and statins (some of which impair CoQ10-dependent mitochondrial function). Researchers designing combination studies should consider these pharmacological interfaces.

Dosing in Research

The following table summarizes dosing parameters from key published SS-31 studies across animal models and clinical trials.

Molecular Properties

Storage and Handling

For optimal stability in research settings, SS-31 should be stored as lyophilized powder at -20°C, where it retains full activity for extended periods (typically 2+ years when kept desiccated). The D-amino acid content and C-terminal amidation provide enhanced stability compared to all-L peptides of similar size, but appropriate storage conditions remain essential for reproducible experimental results.

Once reconstituted in sterile water or bacteriostatic water, solutions should be stored at 2-8°C and used within 14-21 days. For longer storage of reconstituted solutions, aliquoting into single-use volumes and freezing at -20°C is recommended. Avoid repeated freeze-thaw cycles, which may cause aggregation and loss of activity.

The lyophilized powder should be protected from light and moisture. Allow vials to equilibrate to room temperature before opening to prevent moisture condensation on the peptide cake. Given the compound’s amphipathic nature and tendency to partition into lipid bilayers, researchers should avoid polypropylene containers for dilute solutions, as adsorptive losses may be significant; glass or low-binding polypropylene is preferred. Verify peptide integrity periodically using reversed-phase HPLC or mass spectrometry.

Current Research Landscape

SS-31/elamipretide occupies a unique position in the therapeutic landscape as the most clinically advanced mitochondria-targeted peptide compound. Several key research directions define the current and near-future trajectory of the field.

1. Barth syndrome therapeutics: The TAZPOWER clinical program has provided the most compelling clinical evidence for elamipretide to date, consistent with the direct pathophysiological rationale of targeting cardiolipin dysfunction in a disease caused by impaired cardiolipin remodeling. Ongoing investigations continue to evaluate long-term efficacy and the temporal evolution of cardiomyopathic phenotypes in treated patients.

2. Heart failure refinement: While the PROGRESS-HF results were neutral for the primary endpoint, the strong preclinical evidence and the favorable changes observed in the earlier EMBRACE trial suggest that treatment duration, patient selection, and outcome measures may require optimization. The 28-day treatment window in PROGRESS-HF may have been insufficient to observe structural cardiac remodeling, and future trials may focus on longer treatment durations, functional endpoints, or specific heart failure subtypes.

3. Age-related macular degeneration: The ReCLAIM clinical program explored elamipretide for dry age-related macular degeneration (AMD), targeting the mitochondrial dysfunction in retinal pigment epithelial cells that is a hallmark of early AMD pathogenesis.

4. Primary mitochondrial myopathy: The MMPOWER-3 trial evaluated elamipretide in patients with genetically confirmed primary mitochondrial myopathies, representing a heterogeneous group of disorders unified by mitochondrial respiratory chain dysfunction.

5. Next-generation analogs: Structure-activity relationship studies by Mitchell and colleagues have characterized alternative tetrapeptide analogs that differ in aromatic side chain composition and sequence register. Among these, the tryptophan-containing analog SPN10 showed the strongest impact on membrane properties and greatest efficacy in cell culture models, suggesting that next-generation SS peptides with enhanced potency may be achievable through rational design.

6. Mechanistic deepening: Recent comprehensive reviews have synthesized the expanding understanding of elamipretide’s mechanism, moving beyond the initial ROS scavenging hypothesis to encompass cardiolipin binding, membrane electrostatic modulation, protein-lipid interaction optimization, and downstream effects on mitochondrial dynamics, biogenesis, and quality control. This mechanistic clarity is essential for identifying the patient populations most likely to benefit from treatment and for designing optimal clinical trial protocols.

7. Expanding disease applications: Preclinical evidence continues to accumulate for SS-31 in models of diabetic cardiomyopathy, diabetic nephropathy, ischemia-reperfusion injury across multiple organs, neurodegenerative diseases including Alzheimer’s disease, spinal cord injury, atherosclerosis, and various forms of skeletal muscle wasting. The breadth of these applications reflects the fundamental role of cardiolipin and mitochondrial bioenergetics in cellular health across all tissues.

References

The studies referenced throughout this monograph represent a curated selection of the published literature on SS-31/elamipretide. For a comprehensive bibliography, researchers are encouraged to search PubMed using the terms “SS-31,” “elamipretide,” or “Szeto-Schiller peptide” for the most current publications. Over 300 peer-reviewed papers have been published on this compound as of early 2026.